Genentech's giredestrant cuts breast cancer recurrence risk by 30% Dec 10, 2025 08:20AM
Genentech reports positive Phase III results for uveitic macular edema drug Oct 17, 2025 04:23PM
Genentech launches direct-to-patient program for flu drug Xofluza Oct 16, 2025 11:49AM
Genentech breaks ground on $700 million manufacturing facility in North Carolina Aug 25, 2025 02:31PM
FDA rejects Genentech's Columvi combination for lymphoma treatment Jul 18, 2025 11:45AM


Jun 20, 2025 11:48AM Roche's (RHHBY) Genentech presents results from Phase 3 study of Lunsumio
May 12, 2025 10:49AM Roche (RHHBY) to invest $550 million for manufacturing hub expansion
Apr 2, 2025 07:07AM Quest Diagnostics (DGX) Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
Feb 4, 2025 11:46AM FDA Approves Genentech’s Susvimo as Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Jul 17, 2024 11:45AM Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study